Pfizer $PFE announced the acquisition of biotech firm Seagen. This acquisition is another step in Pfizer's efforts to confirm its position as a long-term leader in oncology.
Seagen will bring to Pfizer's portfolio an excellent ADC technology that can deliver a cancer-killing drug directly to cancer cells while sparing other healthy tissues to the maximum extent possible. In the future, we will be able to bring cancer drugs from the antibody conjugate class to patients, which will be a breakthrough technology for the treatment of many types of cancer.
So we'll see how it turns out, as Marek writes, not every acquisition has to be so profitable. However, I have PFE shares in my portfolio and I am waiting for the growth.
I can't really form an opinion on the acquisition. Although it fits their portfolio, I don't know if it was a good deal at that price. I fear that like many of their acquisitions, it will be a long run. But I guess why not.